Read More 6 minute read Pharma Industry News Oral GLP-1 race heats up as Structure Therapeutics posts strong ACCESS data for aleniglipron Find out how Structure Therapeutics’ oral GLP-1 drug aleniglipron delivered double-digit weight loss in the ACCESS trial and what it means for the obesity market. bySoujanya RaviDecember 8, 2025